Dopamine-β-hydroxylase inhibition: A novel sympatho-modulatory approach for the treatment of congestive heart failure

Current Pharmaceutical Design

Volumn 4, Issue 6, 1998, Pages 469-479

  Hegde, S S ^a   Friday, K F ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE BETA MONOOXYGENASE; ENZYME INHIBITOR; NEPICASTAT; NORADRENALIN;

ADRENERGIC SYSTEM; ARTICLE; CONGESTIVE HEART FAILURE; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; DOPAMINE BETA-HYDROXYLASE; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; IMIDAZOLES; SYMPATHETIC NERVOUS SYSTEM; THIONES;

EID: 0031761557     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Thon, T Morbidity and mortality chartbook on cardiovascular, lung and blood diseases, 1990 Bethesda (MD) National Heart, Lung and Blood Institute.
2. Sullivan, M. J. Congestive heart failure: Trends in epidemiology and therapy In: Congestive heart failure: Current clinical issue;. Kennedy, G. T, Crawford, M H, eds Futurea Publishing Company, Inc; Armonk (NY): 1994, p. 1-115.
3. Graves, E. J. Detailed diagnosis and procedures, national hospital discharge survey, 1990. Washington DC: US Dept. HHS, 1991. National Center for Health Statistics series 13, No 113, DHHS Pub No. (PHS) 92-1774.
4. Kannel, W. B.; Ho, K.; Thon, T Changing epidemiological features of cardiac failure. Br. Heart. J, 1994, 72 (Suppl), S3-S59.
5. Williams, J. F. Evolving concepts in congestive heart failure. Part I. Modern Concepts. Cardiovasc Dis. 1990, 59, 43-47.
6. Konstam, M.; Dracup, K.; Baker D. et. al. Heart failure: management of patients with left-ventricular systolic function; Clinical Practice Guideline No 11, Rockville (MD): Agency for Health Care Policy and Research, Public health Service, US Dept HHS; 1994. AHCPR Publication No 94-0612; 1-115
7. Cohn, J. N. The management of chronic heart failure N Eng. J. Med, 1996, 335, 490-498
8. Cohn, J. N. Overview of the treatment of heart failure Am J. Cardiol, 1997, 80 (11A), 2L-6L.
9. Packer M.; Carver JR ; Rodeheffer RJ.; Ivanhoe RJ.; DiBianco R., Zeldis SM.; Hendrix GH., Bommer WJ ; Elkayam U.; Kukin ML ; Mallis GI., Sollano JA.; Shannon J.; Tandon PK.; DeMets, D. L. for the PROMISE Study Research Group Oral milrinone on mortality in severe congestive heart failure N. Eng. J. Med 1988, 325, 1468-1475.
10. Barnett, D B. Flosequinan. Lancet. 1993, 341, 733-736.
11. Packer, M The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol, 1992, 20, 248-254
12. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Surivival Study (CONSENSUS) N. Engl. J. Med 1987, 316, 1429-1435.
13. The SOLVD Investigators Effect of enalapril on survival in patients with reduced lift ventricular ejection fraction and congestive heart failure N Engl J. Med, 1991, 325, 293-302.
14. Packer, M Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure ? Lessons learned from clinical trials with β-adrenergic agonists and antagonists. J Cardiovasc. Pharmacol. 1989, 14, S38-S43.
15. Esler, M.; Kaye, D.; Lambert, G ; Esler, D.; Jennings, G. Adrenergic Nervous System in Heart Failure. Am. J. Cardiol; 1997, 80 (11A): 7L-14L.
16. Thomas, J.A., Marks, B. H Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978, 41, 233-243.
17. Levine, T.B.; Francis, G.S.; Goldsmith, S.R.; Simon, A ; Cohn, J.N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities. Am. J. Cardiol. 1982, 49, 1659-1666.
18. Leimbach, W.N.; Wallin, B.G.; Victor, R. G ; Aylward, P E.; Sundlof, G.; Mark, A. L.; Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation, 1986, 73, 913-919
19. Hasking, G. J.; Esler, M. D.; Jennings, G. L.; Burton, D.; Johns, J. A; Korner, P. I Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity Circulation. 1986, 73, 615-621
20. Rundqvist, B ; Elam, M ; Bergmann-Sverrisdottir, Y.; Eisenhofer, E.; Friberg. P. Increased cardiac adrenergic drive precedes generalised sympathetic activation in human heart failure. Circulation, 1997, 95 169-175
21. Meredith, I. T , Eisenhofer, G ; Lambert, G W.; Dewar, E. M., Jenmngs, G L.; Esler, M D Cardiac sympathetic nervous activity in congestive heart failure Evidence for increased norepinephrine release and preserved neuronal uptake Circulation, 1993, 83, 136-145
22. Baum T. Fundamental principles governing regulation of circulatory function. In 'Cardiovascular Pharmacology, ed by Antonaccio M., Raven Press Ltd, NY, 1990, pp 1-36.
23. Meredith, I T ; Broughton A ; Jennings, G.L; Esler, M. D Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias N. Eng. J. Med. 1991, 325, 618-624.
24. Sabbah, H. N.; Goldberg, A. D.; Schoel, W ; Kono, T., Webb C ; Brachmann J.; Goldstein, S. Spontaneous and inducible ventricular arrhythmias in a canine model of chronic heart failure: relation to haemodynamics and sympathoadrenergic activation Eur. Heart J. 1992, 13, 1562-1572.
25. Rona G. Catecholamine cardiotoxicity. J. Mol. Cell. Cardiol 1985, 17, 291-306.
26. Teerlink, J R.; Pfeffer, J.M.; Pfeffer, M.A Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res. 1994, 75, 105-113.
27. Daly, P.A.; Sole, M.J. Myocardial catecholamines and the pathophysiology of heart failure. Circulation. 1990, 82(suppl I), I-35-I-43.
28. Cohn, J.N.; Levine, B.T.; Olivari, M T.; Garber, V.; Lura, D.; Francis, G.S.; Simon, A.B.; Rector, T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Eng. J Med. 1984, 311, 819-823.
29. Kaye, D. M.; Lefkovits, J.; Jennings, G. L.; Bergin, P.; Esler, M. D. Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol. 1995, 26, 1257-1263.
30. Francis, G.S.; Benedict, C.; Johnstone, D.E ; Kirlin, P.C.; Nicklas, J ; Liang, C-S ; Kubo, S.H ; Rudin-Toretsky, E.; Yusuf, S. for the SOLVD Investigators Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left ventricular Dysfunction (SOLVD). Circulation. 1990, 82, 1724-1729.
31. Benedict, C.R.; Shelton, B , Johnstone, D.E., Francis, G ; Greenberg, B ; Konstam, M , Probstfield, J.L.; Yusuf, S for the SOLVD investigators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction Circulation. 1996, 94, 690-697
32. Waagstein, F., Bristow, M R.; Swedberg, K.; Camerini, F , Fowler, M.B.; Silver, M.A.; Gilbert, E M.; Johnson, M R.; Goss, F.G., Hjalmarson, A. for the Metoprolol in Dilated cardiomyopathy (MDC) trial Study Group.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993, 342,1441-1446
33. The CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: The cardiac insufficiency bisoprolol study (CIBIS) Circulation 1994, 90, 1765-1773.
34. Bristow, M.R ; Gilbert, E M ; Abraham, W.T ; Adams, K F , Fowler, M.B., Hershberger RE., Kubo SH., Narahara KA., Ingersoll H., Krueger S , Young S. and Shusterman N for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure Circulation. 1996, 94, 2807-2816
35. Packer. M.; Bristow, M.R.; Cohn, J N.; Colucci, W S ; Fowler, M.B.; Gilbert, E M.; Shusterman, N.H, for the US Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in chronic heart failure. N. Eng. J. Med 1996, 334, 1349-1355.
36. Australia/New Zealand Heart Failure research Collaborative Group Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease Lancet. 1997, 349, 375-380
37. Yue, T-L ; Cheng, H-Y.; Lysko, P G ; McKenna, P.J.; Feuerstein, R., Gin, J L.; Lysko, K.A.; Davis, L.L. Feuerstein, R Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992, 263, 92-98
38. Pfeffer, M A., Stevenson, L.W β-adrenergic blockers and survival in heart failure. N. Eng. J. Med. 1996, 334, 1396-1397
39. Packer, M. Effects of beta-adrenoceptor blockade on survival of patients with chronic heart failure. Am. J. Cardiol 1997, 80 (11A), 46L-54L.
40. Kaufman, S.; Friedman S, Dopamine-β-hydroxylase. Pharmacol. Rev. 1965, 17, 71-100.
41. Robertson, D ; Haile, V.; Perry, SE., Robertson, R.M.; Phillips, J A. III .; Biaggioni I. Dopamine-beta-hydroxylase deficiency A genetic disorder of cardiovascular regulation. Hypertension 1991, 18, 1-8.
42. Goldstein, M.; Nakajima K. The effect of disulfiram on the biosynthesis of catecholamines during exposure of rats to cold Life Sci. 1966, 5, 175-179
43. Korduba, C.A.; Veals, J.; Wohl, A.; Symchowicz, S.; Tabachnick, A. SCH 10595, an effective dopamine-β-hydroxylase inhibitor and a hypotensive agent. J. Pharmacol. Exp. Ther. 1973, 184, 671-677.
44. Anden, N-E.; Corrodi, H.; Fuxe K. Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine-β-hydroxylase inhibitors. J. Pharm. Pharmacol. 1972, 24, 177-182.
45. Matta, R J.; Wooten G.F. Pharmacology of fusaric acid in man. Clin. Pharmacol. Ther. 1973, 14, 541-546.
46. Claxton, I.M , Palfreyman, M.G.; Poyser, R.H.; Whiting, R.L. BRL 8242 (2-[2-Benzimidazolyl]-amino-2-imidazoline dihydrchloride), a new inhibitor of dopamine-β-hydroxylase inhibitor with antihypertensive activity. Eur. J. Pharmacol. 1976, 37: 179-188
47. Berkowitz, B.A.; Arleth, A.J.; Sung, C.P.; Kruse, L.I., DeWolf, W E ; Ohlstein, E. H. Effects of the novel dopamine-β-hydroxylase inhibitor SK&F 102698 on catecholamines and blood pressure in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 1988, 245, 850-857
48. Stanley, W C.; Li, B.; Bonhaus, D.; Johnson, L. G.; Lee, K.; Porter, S ; Martinez, G.; Eglen, R. M.; Whiting, R. L.; Hegde, S.S Catecholamine modulatory effects of nepicastat (RS 25560-197). a novel, potent and selective inhibitor of dopamine-β-hydroxylase Brit J. Pharmacol. 1997, 21, 803-809.
49. Stanley, W. C.; Hegde, S. S. Dopamine-beta-hydroxylase Inhibition: A potential therapy for the treatment of congestive heart failure. Heart Failure Rev, 1998, 2, 195-201.
50. Lefkowitz, R. J., Hoffman, B. B.; Taylor P. Neurohormonal Transmission: the autonomic and somatic motor nervous systems In The pharmacological basis of therapeutics, edited by Goodman, L. S, Gilman, A., Rall, T. W., Nies, A. S and Taylor, P., McGraw-Hill, Inc, N.Y., 1993; pp 84-121
51. De Quartra, V ; Nagatsu, T.; Mendez, A., Verska, J. Determinants of cardiac noradrenaline depletion in human congestive failure Cardiovasc Res. 1973, 7, 344-350.
52. Lokhandwala, M.F., De Feo, M.L., Cavero, I. Physiological and pharmacological significance of dopamine receptors in the cardiovascular system. Prog. Hyper. 1988, 1, 115-144.
53. Lokhandwala, M. F.; Hegde, S. S. Cardiovascular pharmacology of adrenergic and dopamine receptors: Therapeutic significance in congestive heart failure. Am. J. Med 1991, 90(Suppl 5B), 2S-9S.
54. Stanley, W. C., Lee, K.; Johnson, L. G.; Whiting R L.; Eglen, R M ; Hegde, S. S. Cardiovascular effects of nepicastat (RS-25560-197), a novel inhibitor of dopamine-β-hydroxylase. J Cardiovas. Pharmacol. 1998, 31, 963-970.
55. Sabbah, H. N.; Tammura, M.; Mishima, T.; Benedict, C. R ; Hegde, S. S.; Goldstein, S. Effects of long-term therapy with nepicastat (RS-25560-197), a dopamine-β-hydroxylase inhibitor, on left ventricular function and remodeling in dogs with moderate heart failure Circulation, 1997, 96 (8), abst. 508.
56. Hegde, S. S.; Kramer, J. H ; Mak, I T.; Weglicki, W. B. The novel dopamine-β-hydroxylase inhibitor, nepicastat, and its metabolite provide antioxidative protection to post-ischemic hearts of Mg-restricted rats Faseb. J, 1998, 12 (4), abst 1476.
57. Benedict, C. R.; Gottlieb, S. S., Massie, B R.; Ghali, J. K.; MacKinnon, S. A.; Friday, K. F. Modulation of Sympathetic Activation in patients with heart failure by nepicastat (RS-25560-197): a dopamine-β-hyroxylase inhibitor. Circulation, 1997, 96 (8): abst. 509.